Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT
Explore this paper's citation graph
Summary
A molecular imaging TNM system (miTNM, version 1.0) is proposed as a standardized reporting framework for PSMA-ligand PET/CT or PET/MRI, designed to organize findings in comprehensible categories to promote the exchange of information among physicians and institutions.
- Type
- article
- Published
- 2017-11-09
- Cited by
- 574
- References
- 60
- Access
- Open access
- OpenAlex
- https://openalex.org/W2767249739
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:3611815
Keywords
Prostate cancer, Glutamate carboxypeptidase II, Medicine, Molecular imaging, Prostate
References
- Neuroendocrine differentiation of prostate cancer: a review.
- Multimodal image-guided prostate fusion biopsy based on automatic deformable registration
- Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy.
- A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer
- A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index.
- Prognostic factors influencing prostate cancer‐specific survival in non‐castrate patients with metastatic prostate cancer
- PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions
- BI-RADS update for breast cancer caregivers
- Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy.
- New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
- [68Ga]PSMA-HBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical practice
- Mapping of pelvic lymph node metastases in prostate cancer.
- Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer
- Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results.
- Pathways of lymphatic spread in male urogenital pelvic malignancies.
- The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis.
- Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy.
- Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer.
- Prostate cancer: sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy--results of ACRIN prospective multi-institutional clinicopathologic study.
- Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group.
Cited by
- PSMA PET: Transformational Change in Prostate Cancer Management?
- Prostate-specific membrane antigen theranostics: therapy with lutetium-177
- Proposed Criteria Positions PSMA PET for the Future
- Tracers for Fluorescence-Guided Surgery: How Elongation of the Polymethine Chain in Cyanine Dyes Alters the Pharmacokinetics of a Dual-Modality c[RGDyK] Tracer
- Advances in PSMA Positron Emission Tomography (PET) of Prostate Cancer
- Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer
- Detection Threshold and Reproducibility of 68Ga-PSMA11 PET/CT in a Mouse Model of Prostate Cancer
- Potential Impact of 68Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer
- Meeting report from the Prostate Cancer Foundation PSMA‐directed radionuclide scientific working group
- 68Ga-PSMA-11 PET/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer
- “Das PSMA-PET/CT soll bei allen Patienten mit biochemischem Progress nach radikaler Prostatektomie für eine frühe Tumordetektion eingesetzt werden.”
- Advances in Urologic Imaging: Prostate-Specific Membrane Antigen Ligand PET Imaging.
- Imaging prostate cancer with PSMA PET/CT and PET/MRI: current and future applications
- Molecular imaging reporting and data systems (MI-RADS): a generalizable framework for targeted radiotracers with theranostic implications
- PSMA Ligand PET/MRI for Primary Prostate Cancer: Staging Performance and Clinical Impact
- 68Ga-labelled PSMA ligand HBED-CC PET/CT imaging in patients with recurrent prostate cancer
- Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on 18F-DCFPyL PET/CT Imaging
- Follow-up of Lesions with Equivocal Radiotracer Uptake on PSMA-Targeted PET in Patients with Prostate Cancer: Predictive Values of the PSMA-RADS-3A and PSMA-RADS-3B Categories
- Standardisation of PSMA images interpretation: why do we need it?
- A Systematic Review on the Role of Imaging in Early Recurrent Prostate Cancer.
Related papers
- The Impact of 68Ga-PSMA PET/CT and PET/MRI on the Management of Prostate Cancer.
- Advance of molecular imaging with positron emission tomography
- Development of PET probes for cancer imaging.
- Clinical molecular imaging with positron emission tomography.
- Positron emission tomography provides molecular imaging of biological processes
- Keeping up with the prostate-specific membrane antigens (PSMAs): an introduction to a new class of positron emission tomography (PET) imaging agents
- Positronenemissionstomographie in den Neurowissenschaften
- Small animal positron emission tomography imaging and in vivo studies of atherosclerosis